Market Overview

Clinuvel Pharmaceuticals Receives Unsolicited Proposal from Retrophin to Acquire All Shares In Clinuvel for Either 0.175 Retrophin Shares/Clinuvel Share or $2.17 In Cash/Share

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News M&A

 

Related Articles (CLVLY + RTRX)